Mesoblast (NASDAQ: MESO)
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-29 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.130 | -0.160 | -0.0300 | ||||
REV | 2.011M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Mesoblast (NASDAQ: MESO) through any online brokerage.
Other companies in Mesoblast’s space includes: Humacyte (NASDAQ:HUMA), Centessa Pharmaceuticals (NASDAQ:CNTA), Burning Rock Biotech (NASDAQ:BNR), Tango Therapeutics (NASDAQ:TNGX) and Adaptimmune Therapeutics (NASDAQ:ADAP).
The latest price target for Mesoblast (NASDAQ: MESO) was reported by Chardan Capital on Friday, June 3, 2022. The analyst firm set a price target for 2.50 expecting MESO to fall to within 12 months (a possible -26.04% downside). 2 analyst firms have reported ratings in the last year.
The stock price for Mesoblast (NASDAQ: MESO) is $3.38 last updated August 11, 2022, 8:00 PM UTC.
There are no upcoming dividends for Mesoblast.
Mesoblast’s Q4 earnings are confirmed for Monday, August 29, 2022.
There is no upcoming split for Mesoblast.
Mesoblast is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.